Antibodies specifically binding to API5 proteins

Through antibodies or antigen-binding fragments that specifically bind API5 protein, targeted treatment of API5 protein is solved, and the problems of drug resistance and side effects in existing anti-cancer treatment methods are achieved, and effective against anti-cancer drug-resistant cancers are achieved. Treatment significantly inhibited the growth of cancer cells.

CN118946581APending Publication Date: 2024-11-12NEX I INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380031036.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-30
Filing Date
2023-03-28
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The existing anti-cancer treatment methods are relatively non-selective, resulting in chemotherapy resistance and side effects, and there is a need for new targeted anti-cancer drugs, especially the treatment of specific target API5 proteins.

Method used

Develop antibodies or antigen-binding fragments of the API5 protein specifically bind to the API5 protein, and target therapies to reduce their activity to prevent or treat cancers that are resistant to anti-cancer drugs through high binding ability and excellent anti-cancer effects.

Benefits of technology

It significantly reduces ERK phosphorylation in cancer cells, increases apoptosis sensitivity, inhibits tumor growth, and shows excellent anti-cancer effects, especially in cancer cells that are resistant to existing immunotherapeutic drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118946581A_ABST
    Figure CN118946581A_ABST
Patent Text Reader

Abstract

The invention relates to an antibody specifically binding to an apoptosis inhibition factor 5 (API5) protein and application thereof. According to the present invention, an antibody specifically binding to API5 or an antigen-binding fragment thereof can have excellent anti-cancer effects, such as inhibition of phosphorylation of ERK in cancer cells and inhibition of cancer growth. In addition, the antibody or the antigen-binding fragment thereof exhibits an excellent anti-cancer effect on cancer that is resistant or refractory to an anti-cancer drug. Therefore, it can be used to prevent or treat cancers that are resistant to or refractory to anti-cancer drugs, and general cancers.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to an antibody specifically binding to apoptosis inhibitor 5 (API5) protein and its application. Background Art

[0002] Despite intensive research into cancer over the past few decades, cancer remains a leading cause of death worldwide. Many anti-cancer treatments have been developed, but not all are effective for all cancer types and all patients. Current methods used to treat cancer are relatively non-selective. Diseased tissue is removed surgically, the size of solid tumors is reduced by radiation therapy, or chemotherapy is used to quickly kill cancer cells. However, chemotherapy can cause drug resistance, sometimes limiting the dose that can be administered. This can lead to severe side effects, so they may preclude the use of potentially effective drugs. Therefore, there is a need to develop more targeted and effective cancer therapies.

[0003] In this regard, anticancer targeted drugs that specifically target only cancer cells or anticancer immunotherapy drugs that utilize the patient's immune system are being developed. For example, in South Korea, about 30 anticancer targeted drugs have been approved, and anticancer immunotherapy drugs approved in South Korea include nivolumab (ingredient name: nivolumab), pembrolizumab (ingredient name: pembrolizumab), tadalafil (ingredient name: atezolizumab), phenytoin (ingredient name: durvalumab), ipilimumab (ingredient name: ipilimumab), etc., which are used for various types of cancer, including non-small cell lung cancer, melanoma, renal cell carcinoma, Hodgkin's lymphoma, head and neck cancer, bladder cancer, etc.

[0004] However, when the same anticancer drug or anticancer drugs with the same mechanism are used continuously, new problems such as anticancer drug resistance or refractory may arise. Therefore, since there is still a need for new anticancer drugs in the art, it is necessary to discover cancer cell-specific targets and develop drugs that can be used to prevent or treat cancer.

[0005] Technical issues

[0006] The inventors conducted in-depth research to develop new anticancer drugs. As a result, we prepared a plurality of anti-API5 antibodies that specifically bind to API5 protein, which is a cancer cell-specific target, and confirmed that they have high binding ability to API5 protein and exhibit excellent anticancer effects, thereby completing the present invention. Summary of the invention

[0007] Each description and embodiment disclosed in the present invention is also applicable to other descriptions and embodiments. That is to say, all combinations of various elements disclosed herein fall within the scope of the present invention. In addition, it should not be understood that the scope of the present invention is limited by the following specific description.

[0008] In addition, it should be understood that terms not specifically defined in this specification have meanings commonly used in the technical field to which the present invention belongs. In addition, unless otherwise defined in the context, the singular includes the plural and the plural includes the singular.

[0009] One aspect of the present invention provides an antibody or an antigen-binding fragment thereof that specifically binds to API5 (apoptosis inhibitor 5).

[0010] The term "antibody" as used herein refers to an immunoglobulin molecule that is immunoreactive with a specific antigen, or a protein molecule that is used as a receptor for specific antigen recognition. In the present invention, "antibody" is used in a broad sense, including polyclonal antibodies, monoclonal antibodies, whole antibodies (antibodies formed by at least two heavy chains and two light chains connected by disulfide bonds) and antibody fragments. Whole antibodies include IgA, IgD, IgE, IgM and IgG. In addition, IgG can include IgG1, IgG2, IgG3 and IgG4 as subtypes. The term "antibody fragment" refers to an antigen-binding fragment or analog of an antibody that retains the binding specificity of at least some of the parent antibodies and contains a part of the variable region or antigen-binding region of the parent antibody (e.g., one or more CDRs). Antibody fragments are, for example, Fab, Fab', F(ab')2, Fv fragments, scFv, one-armed antibodies, diabodies, linear antibodies, nanobodies, domain antibodies or multispecific antibodies formed by antibody fragments. The term "API5 (apoptosis inhibitor 5) protein" used herein refers to a protein encoded by the API5 gene, and the amino acid sequence constituting it is known in existing databases (NCBI reference sequences: XP_016873953.1, XP_01687354.1, XP_006718422.1, etc.). The API5 protein is expressed at high levels in tumors such as solid cancers and metastatic cancers, and its expression is particularly increased in cancer cells that are resistant or refractory to anticancer drugs (Han Sol Jang et al. Exp Mol Med. 2017 Sep 8, 49 (9): e374). It is known that the API5 protein phosphorylates and activates ERK1 / 2, thereby inducing tumor development through cell cycle arrest and apoptosis inhibition (Hanbyoul Cho et al. BMC Cancer. 2014 Jul 28, 14: 545).

[0011] The term "anti-API5 antibody" used herein refers to an antibody or antigen-binding fragment thereof that specifically binds to API5 protein and neutralizes or inhibits the activity of API5 protein. Specifically, the anti-API5 antibody can be a human antibody that targets human API5 protein and is also reactive to API5 protein derived from mouse or rat.

[0012] The term "human antibody" as used herein refers to antibodies whose framework and CDR regions have variable regions derived from human immunoglobulin sequences, also referred to as "fully human antibodies". The human antibodies of the present invention may contain amino acid residues not encoded by human immunoglobulin sequences (e.g., mutations introduced by random or site-directed mutagenesis in vitro or somatic mutations in vivo).

[0013] In one embodiment of the present invention, the anti-API5 antibody may comprise a heavy chain CDR1 comprising the amino acid sequence GFTFSTYA shown in SEQ ID NO: 1; a heavy chain CDR2 comprising the amino acid sequence ISGSGGX1T shown in SEQ ID NO: 2; and a heavy chain CDR3 comprising the amino acid sequence AKLVLX2WX3YFSMDH shown in SEQ ID NO: 3, wherein X1, X2 and X3 are independently any amino acid. The amino acid may be arginine (R), histidine (H), lysine (K), aspartic acid (D), glutamic acid (E), serine (S), threonine (T), asparagine (N), glutamine (Q), cysteine ​​(C), selenocysteine ​​(U), glycine (G), proline (P), alanine (A), valine (V), isoleucine (I), leucine (L), methionine (M), phenylalanine (F), tyrosine (Y) or tryptophan (W). Preferably, X1 may be lysine (K) or leucine (L), X2 may be lysine (K) or tryptophan (W), and X3 may be tryptophan (W) or phenylalanine (F), but are not limited thereto.

[0014] The heavy chain CDR2 may include the amino acid sequence shown in SEQ ID NO: 4 or SEQ ID NO: 5, or may include the amino acid sequence shown in SEQ ID NO: 4 or SEQ ID NO: 5, but is not limited thereto.

[0015] Furthermore, the heavy chain CDR3 may be selected from the group consisting of any one of the amino acid sequences of SEQ ID NO: 6 to SEQ ID NO: 10, or may include a sequence selected from the group consisting of SEQ ID NO: 6 to SEQ ID NO: 10, but is not limited thereto.

[0016] In the present invention, the anti-API5 antibody comprises a heavy chain variable region, wherein the heavy chain variable region may be any amino acid sequence selected from the group of SEQ ID NOs: 11 to 15, or may comprise any amino acid sequence selected from the group of SEQ ID NOs: 11 to 15, but is not limited thereto.

[0017] In addition, the anti-API5 antibody comprises light chain CDR1 to CDR3, wherein the light chain CDR1 can be the amino acid sequence shown in SEQ ID NO: 16, or can include the amino acid sequence shown in SEQ ID NO: 16; the light chain CDR2 can be the amino acid sequence shown in SEQ ID NO: 17, or can include the amino acid sequence shown in SEQ ID NO: 17; the light chain CDR3 can be the amino acid sequence shown in SEQ ID NO: 18, or can include the amino acid sequence shown in SEQ ID NO: 18, but is not limited thereto.

[0018] Furthermore, the anti-API5 antibody comprises a light chain variable region, wherein the light chain variable region may be the amino acid sequence shown in SEQ ID NO: 19, or may comprise the amino acid sequence shown in SEQ ID NO: 19, but is not limited thereto.

[0019] The sequences disclosed in the present invention include sequences that show substantial identity with the sequences described in the sequence table. Substantial identity means that the two sequences are aligned to compare as much as possible, and analyzed using algorithms commonly used in the art, and then show 80%, 90%, 95% or higher sequence homology.

[0020] In addition, the antibody or antigen-binding fragment thereof of the present invention may comprise the sequence of the antibody or antigen-binding fragment described herein, a sequence having substantial identity thereto, and a biological equivalent to the extent that it can specifically recognize and bind to the API5 protein. For example, it may comprise additional mutations in the sequence to improve the antibody binding affinity and / or biological properties, as well as additional mutations within the range that do not change the overall activity of the molecule.

[0021] Another aspect of the present invention provides a nucleic acid encoding an antibody or an antigen-binding fragment thereof.

[0022] In the nucleic acid of the present invention, unless otherwise specifically stated, the related terms should be understood to have the same meanings as the above terms.

[0023] The term "nucleic acid" as used herein includes DNA (gDNA and cDNA) and RNA. The nucleotides constituting the basic structural units in nucleic acid molecules include natural nucleotides and analogous nucleotides with modified sugars or bases (Scheit, Nucleotide Analogs, John Wiley, New York (1980); Uhlman and Peyman, Chemical Review, 90: 543-584 (1990)).

[0024] According to the present invention, the nucleic acid molecule encoding the antibody or antigen-binding fragment thereof includes a nucleotide sequence encoding the amino acid sequence constituting the antibody or antibody-binding fragment thereof, but is not limited to any specific nucleotide sequence.

[0025] Taking into account codon degeneracy, nucleotide sequences include nucleotide sequences comprising functionally equivalent codons or codons encoding the same amino acid (e.g., due to codon degeneracy, there are six codons for arginine or serine), or codons encoding biologically equivalent amino acids.

[0026] Considering the mutation with above-mentioned biological equivalent activity, the nucleic acid molecule of the present invention encoding antibody or its antigen-binding fragment includes the sequence that shows substantial identity with it.Substantial identity means that by comparing two sequences to correspond as much as possible, then using the algorithm commonly used in the art to analyze, the result shows 80%, 90% or 95% or more sequence homology.

[0027] Another aspect of the present invention provides a vector comprising the nucleic acid and a cell transformed with the vector.

[0028] In the vectors and transformed cells of the present invention, unless otherwise specifically stated, the relevant terms should be understood to have the same meanings as the above terms.

[0029] The term "vector" as used herein refers to any vector that is inserted into a host cell and capable of gene replication. Vectors include plasmids, linear nucleic acids, cosmids, RNA vectors, viral vectors, etc., and viral vectors include but are not limited to retroviruses, adenoviruses, adeno-associated viruses, etc. The recombinant vector system of the present invention can be constructed by various methods known in the art. In addition, the vector of the present invention can be constructed as a vector for cloning or expression, and can be constructed using prokaryotic or eukaryotic cells as hosts.

[0030] In addition, the transformed cell can be a prokaryotic cell, a eukaryotic cell or an animal cell. The host cell of appropriate selection can be transformed with a vector, and used to express and / or secrete the target protein. The host cell can be an immortalized hybridoma cell, N / SO myeloma cell, 293 cell, HuT 78 cell, CHO cell, HELA cell, COS cell, etc. However, they are not limited thereto, and any host cell known in the art can be used as a host cell of the present invention.

[0031] Another aspect of the present invention provides a pharmaceutical composition for preventing or treating cancer, comprising an antibody or an antigen-binding fragment thereof.

[0032] In the pharmaceutical composition of the present invention, unless otherwise specifically stated, the relevant terms should be understood to have the same meanings as the above terms.

[0033] The term "treatment" as used herein refers to any event in which cancer is improved, reversed or completely cured by administering the composition of the present invention. The term "prevention" as used herein refers to any event in which the occurrence or recurrence of cancer is inhibited, delayed or blocked by administering the composition of the present invention.

[0034] In the present invention, cancer may show resistance, tolerance or refractory to anticancer drugs. The term "anticancer drug resistance" or "anticancer drug tolerance" as used herein means that when anticancer drugs are used to treat cancer patients, there is no effect from the beginning of treatment, or there is a therapeutic effect at the beginning of treatment, but it decreases or loses during the continuous treatment. In addition, the term "anticancer drug refractory" as used herein means that when anticancer drugs are used to treat cancer patients, there is no effect from the beginning of treatment, or the response to treatment cannot be sustained for a long time.

[0035] The API5 disclosed in the present invention shows increased expression in cancer cells and activates ERK signaling to impart resistance or refractory to anticancer drugs such as chemotherapeutic drugs or immunotherapy drugs. Therefore, the antibody or antigen-binding fragment thereof that specifically binds to the API5 protein of the present invention can reduce or decrease the activity of the API5 protein, and thus it is very useful for preventing or treating cancers that are resistant or refractory to existing anticancer drugs.

[0036] For example, existing anti-cancer drugs may include anti-cancer chemotherapy drugs known to be resistant or refractory, such as 5-FU, methotrexate, gemcitabine, cytarabine, paclitaxel, vinorelbine, cisplatin, oxaliplatin and irinotecan, anti-cancer targeted drugs such as bortezomib, cetuximab, crizotinib, dasatinib, gefitinib, imatinib and vemurafenib, and / or anti-cancer immunotherapy drugs such as CTLA-4 inhibitors, PD-1 inhibitors, PD-L1 inhibitors and ACT (adoptive cell therapy), but are not limited thereto.

[0037] In addition, the cancer can be one or more selected from the group consisting of lung cancer, non-small cell lung cancer, colorectal cancer, rectal cancer, proximal anal cancer, colon cancer, small intestine cancer, breast cancer, uterine cancer, ovarian cancer, fallopian tube cancer, endometrial cancer, cervical cancer, vaginal cancer, vulvar cancer, head cancer, neck cancer, thyroid cancer, parathyroid cancer, stomach cancer, liver cancer, pancreatic cancer, bone cancer, skin cancer, skin or intraocular melanoma, Hodgkin's disease, esophageal cancer, endocrine cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, penile cancer, prostate cancer, bladder cancer, kidney cancer, ureteral cancer, renal cell carcinoma, renal pelvis cancer, central nervous system tumors, central nervous system lymphomas, spinal cord tumors, glioblastomas, brain stem gliomas, and pituitary tumors, but are not limited thereto.

[0038] The pharmaceutical composition of the present invention, including an effective amount of an antibody or an antigen-binding fragment thereof, can be administered to a subject in need of preventing or treating cancer.

[0039] The term "administration" as used herein refers to physically administering a composition to a subject using any of a variety of methods or delivery systems known to those skilled in the art. Administration can be, for example, oral administration, or intravenous, intramuscular, subcutaneous, intraperitoneal, spinal or other parenteral administration, such as administration by injection or infusion, but is not limited thereto. For example, the number of administrations can be a single, multiple, or over one or more extended time periods.

[0040] The term "subject" as used herein includes humans or any non-human animals, which may be vertebrates, such as primates, dogs, cows, horses, pigs, rodents, such as mice, rats, guinea pigs, etc. In the present invention, "subject" is used interchangeably with "individual" and "patient".

[0041] The effective amount can be a "therapeutically effective amount" or a "prophylactically effective amount". The term "therapeutically effective amount" refers to any amount that can reduce the severity of disease symptoms, increase the frequency and duration of disease-free periods, or prevent damage or disability caused by the disease. The term "prophylactically effective amount" refers to any amount that inhibits the occurrence or recurrence of cancer in a subject. The level of the effective amount can be determined based on the severity of the subject, age, sex, drug activity, drug sensitivity, administration time, route of administration and excretion rate, treatment cycle, concurrent medications, and other factors well known in the medical field.

[0042] In addition, the dosage of the pharmaceutical composition can vary according to the age, sex and weight of the subject. Specifically, 0.1 to 100 mg / kg of the composition of the present invention can be administered once or several times a day, or every few days to several months, according to the symptoms of the subject. In addition, the dosage can be increased or decreased according to the route of administration, severity of the disease, sex, weight, age, etc.

[0043] In addition, the pharmaceutical composition may also include suitable carriers, excipients and diluents commonly used in the preparation of pharmaceutical compositions. The carriers, excipients and diluents that may be included in the composition include, for example, lactose, glucose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum arabic, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylparaben, propylparaben, talc, magnesium stearate and mineral oil, but are not limited thereto.

[0044] In addition, the pharmaceutical composition can be administered in combination with other therapeutic drugs. In this case, the pharmaceutical composition of the present invention and other therapeutic drugs can be administered simultaneously, sequentially or separately. Other therapeutic drugs can be drugs with the effect of preventing, treating and alleviating cancer, such as compounds or proteins, but are not limited thereto.

[0045] In addition, the pharmaceutical composition can be formulated to be administered simultaneously, sequentially or separately with other therapeutic drugs. For example, the antibody or its antigen-binding fragment and other therapeutic drugs can be administered simultaneously in one preparation, or simultaneously, sequentially or separately in separate preparations. For simultaneous, sequential or separate administration, the antibody or its antigen-binding fragment and other therapeutic drugs contained in the pharmaceutical composition of the present invention can be separately formulated in different containers, or can be formulated together in the same container. In addition, they can have the same or different effective drug amounts, administration times, administration intervals, administration routes, treatment periods, etc.

[0046] Another aspect of the present invention provides a method for preventing or treating cancer, comprising administering an antibody or an antigen-binding fragment thereof.

[0047] In the method for preventing or treating of the present invention, unless otherwise specified, the relevant terms should be understood to have the same meanings as the above terms.

[0048] Furthermore, in the method for preventing or treating cancer of the present invention, the antibody or antigen-binding fragment thereof can be administered to a subject simultaneously, sequentially or separately with other therapeutic drugs.

[0049] "Simultaneous" administration refers to a one-time administration of an antibody or its antigen-binding fragment and other therapeutic drugs in one preparation, or a one-time administration of an antibody or its antigen-binding fragment and other therapeutic drugs in a separate preparation. In this case, the administration routes of the antibody or its antigen-binding fragment and other therapeutic drugs may be different from each other. In addition, "sequential" administration refers to relatively continuous administration of an antibody or its antigen-binding fragment and other therapeutic drugs, consuming as little time as possible within the dosing interval. In addition, "single" administration refers to administration of an antibody or its antigen-binding fragment and other therapeutic drugs at predetermined time intervals. Taking into account the therapeutic effect and side effects of the subject, a doctor or expert in the field can appropriately select a method for administering an antibody or its antigen-binding fragment and other therapeutic drugs.

[0050] Another aspect of the present invention provides a composition for diagnosing cancer, comprising an antibody or an antigen-binding fragment thereof.

[0051] Another aspect of the present invention provides a kit for diagnosing cancer, comprising an antibody or an antigen-binding fragment thereof.

[0052] In the composition and kit for diagnosing cancer of the present invention, unless otherwise specified, the relevant terms are understood to have the same meanings as the above terms.

[0053] It is known that the API5 protein disclosed in the present invention is overexpressed in various types of cancer cells, including cancers that are resistant or refractory to anticancer drugs and general cancers. Therefore, the antibodies or antigen-binding fragments thereof that bind to the API5 protein with high specificity and affinity in the present invention can be used to diagnose cancers of diseases associated with the expression level or presence of the API5 protein.

[0054] Specifically, the cancer diagnosis of the present invention can be determined by reacting the antibody or its antigen-binding fragment with a biological sample to determine whether cancer has occurred or is likely to develop, and preferably, by contacting the antibody or its antigen-binding fragment with a biological sample to determine whether an antigen-antibody complex is formed.

[0055] The term "biological sample" as used herein includes tissues, cells, blood, serum, plasma, tissue autopsy samples (brain, skin, lymph nodes, spinal cord), etc., but is not limited thereto.

[0056] The term "antigen-antibody complex" used herein refers to a complex formed by the binding of the API5 protein antigen in a sample to the antibody or antigen-binding fragment thereof that recognizes the API5 protein in the present invention.

[0057] The formation of such antigen-antibody complexes can be detected by any method, such as colorimetry, electrochemical method, fluorescence method, chemiluminescence method, particle counting method, visual assessment or scintillation counting method. However, it is not limited thereto, and various applications and modifications can be performed according to methods known in the art.

[0058] Specifically, the diagnostic composition or kit of the present invention can be prepared to be suitable for various immunoassays or immunostainings. Immunoassays or immunostainings include, but are not limited to, enzyme-linked immunosorbent assay (ELISA), immunofluorescence, Western blotting, immunohistochemical staining, flow cytometry, immunocytochemistry, radioimmunoassay (RIA), immunoprecipitation assays, and protein chips.

[0059] Furthermore, labels used for qualitatively or quantitatively determining the formation of an antigen-antibody complex include enzymes, fluorescent substances, ligands, luminescent substances, microparticles, redox molecules, and radioactive isotopes, but are not limited thereto.

[0060] Another aspect of the present invention provides a method for providing cancer diagnostic information, comprising detecting API5 protein in a biological sample isolated from a subject suspected of having cancer or determining the expression level of API5 protein by using an antigen-antibody reaction of an antibody or an antigen-binding fragment thereof.

[0061] In the method for providing information for cancer diagnosis of the present invention, unless otherwise specified, the relevant terms are understood to have the same meanings as the above terms.

[0062] In the present invention, the method for providing cancer diagnostic information can be performed by reacting an antibody or an antigen-binding fragment thereof with a biological sample to determine whether cancer has occurred or is likely to develop, and preferably, by contacting the antibody or the antigen-binding fragment thereof with the biological sample to determine whether an antigen-antibody complex is formed.

[0063] In one embodiment according to the present invention, the method for providing information for cancer diagnosis can be a cancer diagnosis method, an information providing method for selecting cancer patients who are resistant or refractory to anticancer drugs, or a method for selecting cancer patients who are resistant or refractory to anticancer drugs.

[0064] Specifically, the method includes (a) treating a biological sample isolated from a subject suspected of having cancer with an antibody or an antigen-binding fragment thereof to detect API5 protein through an antigen-antibody reaction; and (b) comparing the level of API5 protein detected in step (a) with that of a control group, and if the level of API5 protein is higher than that of the control group, determining that the subject has cancer.

[0065] Here, the control group may be a biological sample isolated from a healthy person without cancer or a person who has been cured of cancer.

[0066] Another aspect of the present invention provides a method for screening anticancer drugs, comprising (a) treating cancer cells with an anticancer drug candidate; (b) using an antibody or an antigen-binding fragment thereof to determine the expression level of API5 protein in cancer cells treated with the anticancer drug candidate; and (c) when the API5 protein expression level in step (b) is lower than that in cancer cells not treated with the anticancer drug candidate, determining the anticancer drug candidate treated in step (a) as an anticancer drug.

[0067] In the anticancer drug screening method according to the present invention, unless otherwise specified, the relevant terms should be understood to have the same meanings as the above terms.

[0068] Specifically, step (a) is a step of treating cancer cells with an anticancer drug candidate, and can be performed using methods known in the art. For example, the anticancer drug candidate can treat cancer cells and co-culture, or be administered to a living body with cancer cells. However, it is not limited thereto, and those skilled in the art will be able to use methods suitable for the purposes of the present invention.

[0069] The term "anti-cancer drug" as used herein refers to an agent that exhibits a preventive or therapeutic effect on cancer, particularly an agent that can kill cancer cells or tumors or inhibit their growth. In this specification, "anti-cancer drug" can be used interchangeably with "drug", and "treatment" can be used interchangeably with "addition" or "administration".

[0070] The term "anti-cancer drug candidate" as used herein refers to an agent expected to exhibit a preventive or therapeutic effect on cancer, particularly an agent expected to kill cancer cells or tumors or inhibit their growth.

[0071] Preferably, anticancer drugs or anticancer drug candidates include, but are not limited to, compounds, proteins, fusion proteins, compound-protein complexes, drug-protein complexes, antibodies, compound-antibody complexes, drug-antibody complexes, amino acids, peptides, viruses, carbohydrates, lipids, nucleic acids, extracts, fragments, etc. For example, they may include, but are not limited to, compounds, peptides, peptide mimetics, fusion proteins, antibodies, aptamers, antibody-drug conjugates (ADCs), etc. Preferably, they may be antibodies or immuno-oncology agents.

[0072] Step (b) is a step of determining the expression level of API5 protein, and any method known to those skilled in the art can be used. For example, Western blotting, immunoprecipitation assay, enzyme-linked immunosorbent assay (ELISA), tissue immunostaining, flow cytometry analysis, etc. can be used, but not limited thereto, and those skilled in the art will be able to use methods suitable for the purpose of the present invention.

[0073] Step (c) is a step for determining whether the anticancer drug candidate can be used as an anticancer drug. Since the API5 protein is overexpressed in cancer cells and promotes the proliferation, migration, invasion and growth of cancer cells, the anticancer drug candidate that reduces the expression level of the API5 protein can be used as an anticancer drug. In addition, the API5 protein is overexpressed in cancer cells that are resistant or refractory to anticancer drugs, and promotes the proliferation, migration, invasion and growth of cancer cells that are resistant or refractory to anticancer drugs, so the anticancer drug candidate that reduces the expression level of the API5 protein can be used as an anticancer drug for preventing or treating cancers that are resistant or refractory to anticancer drugs.

[0074] The antibody or antigen-binding fragment thereof that specifically binds to API5 according to the present invention can have excellent anti-cancer effects, such as inhibiting the phosphorylation of ERK in cancer cells and inhibiting cancer growth. In addition, the antibody or antigen-binding fragment thereof shows excellent anti-cancer effects on cancers that are resistant or refractory to anticancer drugs. Therefore, it can be used to prevent or treat cancers that are resistant or refractory to anticancer drugs and general cancers. BRIEF DESCRIPTION OF THE DRAWINGS

[0075] Figure 1 The results of Western blotting of phosphorylated ERK (pERK) and ERK show that anti-API5 antibodies No. 1 to 5 (hereinafter referred to as "anti-API5 antibodies of the present invention") with specific heavy chain CDR sequences are expressed in TC-1P3 PD-1 It reduces the phosphorylation of ERK.

[0076] Figure 2 The anti-API5 antibodies No. 1 to No. 5 of the present invention are effective against TC-1P3 PD-1 Figure 3 is a graph of the concentration-dependent reduction in ERK phosphorylation and relates to the ratio of ERK phosphorylated to total ERK.

[0077] Figure 3 The results of Western blotting of phosphorylated ERK (pERK) and ERK show that the anti-API5 antibodies No. 1 to No. 5 of the present invention have an effect on TC-1P3 PD-1 、MC38 P3 PD-1 and CT26 P3 PD-1 The phosphorylation of ERK was reduced.

[0078] Figure 4 The anti-API5 antibodies No. 3 to No. 5 of the present invention are effective against TC-1P3 PD-1 and CT26 P3 PD-1 A diagram showing the apoptosis-enhancing effect of .

[0079] Figure 5A graph showing the tumor growth inhibitory effects of anti-API5 antibodies No. 2 to No. 5 of the present invention in an in vivo melanoma model refractory to anti-cancer immunotherapy drugs. **** indicates p value < 0.0001.

[0080] Figure 6 This is a graph showing the tumor growth inhibitory effect of the anti-API5 antibody No. 1 of the present invention in colorectal cancer refractory to anti-cancer immunotherapy agents or in an in vivo model of colorectal cancer. * indicates p value < 0.05, **** indicates p value < 0.0001.

[0081] Figure 7 This is a graph showing the tumor growth inhibitory effect of the anti-API5 antibody No. 1 of the present invention in an in vivo model of non-small cell lung cancer or cervical cancer. *** indicates p value < 0.001.

[0082] Figure 8 It is a graph showing the tumor growth inhibition effect of anti-API5 antibodies No. 1 to 5 of the present invention in colorectal cancer refractory to anti-cancer immunotherapy drugs or in vivo models of colorectal cancer. * indicates p value < 0.05, *** indicates p value < 0.001, and **** indicates p value < 0.0001.

[0083] Fig. 9 It is a graph showing the tumor growth inhibition effect of the anti-API5 antibody No. 1, anti-PD-1 antibody (catalog #BE0146, purchased from BioXcell) or the combination of the anti-API5 antibody No. 1 and anti-PD-1 antibody of the present invention in an in vivo model of colorectal cancer refractory to anti-cancer immunotherapy drugs. *** indicates p value <0.0001.

[0084] Fig.10 It is a graph showing the tumor growth inhibitory effect of anti-API5 antibodies No. 1 to 4 of the present invention in an in vivo model of colorectal cancer refractory to anti-cancer immunotherapy drugs. *** indicates p value < 0.001, **** indicates p value < 0.0001.

[0085] Fig.11 It is a graph showing the tumor growth inhibition rate of anti-API5 antibodies No. 1 to 4 of the present invention in an in vivo model of colorectal cancer refractory to anti-cancer immunotherapy drugs. DETAILED DESCRIPTION

[0086] Example

[0087] Hereinafter, the present invention will be explained in more detail by examples. These examples are intended to explain the present invention in more detail, and the scope of the present invention is not limited by these examples.

[0088] Example 1. Preparation of anti-API5 antibodies

[0089] The inventors have experimentally demonstrated that antibodies having the specific heavy chain CDR sequences shown in Table 1 below have high affinity for API5.

[0090] Specifically, the variable domain base sequences of the heavy and light chains encoding the anti-API5 antibody were synthesized and inserted into the pCDNA3.4 vector expressing the IgG4 framework to construct an antibody expression vector. The heavy and light chain expression vectors were introduced into ExpiCHO cells and transiently expressed to secrete antibodies to the culture medium. Protein A affinity chromatography was used to purify the antibodies secreted into the culture medium. The concentration and purity of the protein were determined by measuring the absorbance at 280 nm and SDS-PAGE, respectively.

[0091] On the other hand, it is known that among the various sequences constituting antibodies, six CDR sequences including three CDR sequences in the light chain variable region and three CDR sequences in the heavy chain variable region are important for antigen binding. In addition, it is known that the third CDR sequence CDR3 of the heavy chain variable region responsible for the diversity of antibody structure is a particularly important part thereof (Brian D. Weitzner et al., Structure., 2015 Feb 3, 23 (2): 302-311). Therefore, manipulating the CDR3 of the heavy chain variable region has become a method required for antibody development, and thus the anti-API5 antibody of the present invention is prepared by designing only the heavy chain CDR2 and heavy chain CDR3 sequences differently. The anti-API5 antibody thus prepared has the sequence listed in Table 1 below.

[0092] Table 1

[0093] CDR Type Amino acid sequence Serial Number Heavy chain CDR1 GFTFSTYA SEQ ID NO:1 Heavy chain CDR2 <![CDATA[ISGSGGX1T]]> SEQ ID NO:2 Heavy chain CDR3 <![CDATA[AKLVLX2WX3YFSMDH]]> SEQ ID NO:3

[0094] In Table 1, X1, X2 and X3 are independently any amino acid.

[0095] In the present specification, five representative antibodies (anti-API5 antibodies No. 1 to 5) among the anti-API5 antibodies having the sequences shown in Table 1 were used.

[0096] Specifically, anti-API5 antibody No. 1 has a heavy chain CDR1 shown in SEQ ID NO: 3, a heavy chain CDR2 shown in SEQ ID NO: 4, and a heavy chain CDR3 shown in SEQ ID NO: 6, and has a heavy chain variable region shown in SEQ ID NO: 11 and a light chain variable region shown in SEQ ID NO: 19.

[0097] Furthermore, anti-API5 antibody No. 2 has a heavy chain CDR1 shown in SEQ ID NO: 3, a heavy chain CDR2 shown in SEQ ID NO: 4, and a heavy chain CDR3 shown in SEQ ID NO: 7, and has a heavy chain variable region shown in SEQ ID NO: 12 and a light chain variable region shown in SEQ ID NO: 19.

[0098] Furthermore, anti-API5 antibody No. 3 has a heavy chain CDR1 shown in SEQ ID NO: 3, a heavy chain CDR2 shown in SEQ ID NO: 4, and a heavy chain CDR3 shown in SEQ ID NO: 8, and has a heavy chain variable region shown in SEQ ID NO: 13 and a light chain variable region shown in SEQ ID NO: 19.

[0099] Furthermore, anti-API5 antibody No. 4 has a heavy chain CDR1 shown in SEQ ID NO: 3, a heavy chain CDR2 shown in SEQ ID NO: 4, and a heavy chain CDR3 shown in SEQ ID NO: 9, and has a heavy chain variable region shown in SEQ ID NO: 14 and a light chain variable region shown in SEQ ID NO: 19.

[0100] Furthermore, anti-API5 antibody No. 5 has a heavy chain CDR1 shown in SEQ ID NO: 3, a heavy chain CDR2 shown in SEQ ID NO: 5, and a heavy chain CDR3 shown in SEQ ID NO: 10, and has a heavy chain variable region shown in SEQ ID NO: 15 and a light chain variable region shown in SEQ ID NO: 19.

[0101] Example 2. Binding activity of anti-API5 antibodies to API5 protein

[0102] In order to examine the ability of the anti-API5 antibody prepared in Example 1 to bind to API5, the binding kinetics were analyzed.

[0103] Specifically, the binding ability of purified anti-API5 antibodies to API5 protein was analyzed separately using Biacore T200. API5 was immobilized on a sensor chip, and anti-API5 antibodies were used as analytes to determine the binding rate constant (ka) and dissociation rate constant (kd) values. The data of dissociation (kd) and binding (ka) rate constants were calculated using the Biacore evaluation software, and the equilibrium dissociation constant (KD) was calculated based on the ratio of kd to ka. The binding rate constant (ka) represents the rate of complex formation, that is, the number of antigen-antibody complexes formed per second in 1 molar API5 and anti-API5 antibody solution. The unit of ka is 1 / Ms. The dissociation rate constant (kd) represents the stability of the complex, that is, the rate at which the complex dissociates per second. The unit of kd is 1 / s. For example, kd = 0.01 1 / s, indicating that 1% of the complex decays within 1 second. When the value of the equilibrium dissociation constant (KD) calculated based on the ratio of kd to ka is 1×10 -9 M or less, it is determined that the binding ability of the antibody to the antigen protein is excellent.

[0104] Table 2

[0105] Analytes ka(l / Ms) kd(1 / s) KD(M) Anti-API5 Antibody No. 1 <![CDATA[1.91×10 5 ]]> <![CDATA[1.29×10 -4 ]]> <![CDATA[6.76×10 -10 ]]> Anti-API5 Antibody No. 2 <![CDATA[1.79×10 5 ]]> <![CDATA[1.08×10 -4 ]]> <![CDATA[6.02×10 -10 ]]> Anti-API5 antibody No. 3 <![CDATA[2.38×10 5 ]]> <![CDATA[1.07×10 -4 ]]> <![CDATA[4.51×10 -10 ]]> Anti-API5 antibody No. 4 <![CDATA[3.13×10 6 ]]> <![CDATA[7.59×10 -4 ]]> <![CDATA[2.43×10 -11 ]]> Anti-API5 antibody No. 5 <![CDATA[5.43×10 6 ]]> <![CDATA[1.47×10 -4 ]]> <![CDATA[2.71×10 -11 ]]>

[0106] As a result, as shown in the above Table 2, it was confirmed that anti-API5 antibodies No. 1 to 5 had excellent binding ability to API5 protein.

[0107] Example 3. The therapeutic effect of anti-API5 antibodies on cancer

[0108] Example 3-1. Reduction of phosphorylated ERK (pERK)

[0109] In order to examine the anti-cancer effect of the anti-API5 antibody prepared in Example 1, the effect of the anti-API5 antibody on reducing ERK activation (i.e., ERK phosphorylation) in cancer cells was analyzed. ERK is mainly activated by growth factors involved in cell proliferation, differentiation, and survival. ERK activation is achieved through phosphorylation of the ERK protein, and sustained activation of ERK plays an important role in tumorigenesis. It is known that ERK activation is increased in various types of tumors, such as pancreatic cancer, colorectal cancer, lung cancer, ovarian cancer, renal cancer, and breast cancer.

[0110] Specifically, TC-1P3 cells of non-small cell lung cancer or uterine cancer resistant to anti-PD-1 antibody treatment were cultured in RPMI medium containing 5% FBS. PD-1 Cell lines, MC38 P3 for colorectal cancer PD-1 Cell lines and colorectal cancer CT26 P3 PD-1 The cell lines were grown at 1.5 × 10 5Cells were seeded in 12-well plates. Two hours later, the medium was replaced with RPMI medium containing 0.1% FBS and treated with each anti-API5 antibody at a concentration of up to 150 ng / mL.

[0111] After 24 hours, the cells were washed with 1×PBS buffer solution and placed in 150 μL RIPA buffer at 4°C for 10 minutes to induce cell lysis. Then, the cells were centrifuged at 13,000 rpm for 15 minutes at 4°C to obtain a cell extract as a supernatant. Protein was quantified using the Bradford assay, and ERK protein and its phosphorylation level were measured by SDS-PAGE western blotting. The measured ERK protein level and ERK protein phosphorylation level were quantified using Image J (densitometer), and the ratio of phosphorylated ERK protein content to total ERK protein concentration was calculated.

[0112] Here, IgG4 S228P Antibody-treated or untreated mice served as the control group (Con).

[0113] "TC-1P3 PD-1 ”, “MC38 P3 PD-1 or CT26 P3 PD-1 “refers to cells resistant to anti-PD-1 antibody treatment, which survive three subcultures of parental cancer cells “TC-1P0”, “MC 38P0” or “CT26 P0” with anti-PD-1 viral antibodies.

[0114] result, Figure 1 Shown, compared with IgG4 S228P Compared with the antibody-treated control group, ERK phosphorylation was significantly reduced in the experimental groups treated with No. 1 to 5 anti-API5 antibodies of the present invention.

[0115] also, Figure 2 It was shown that ERK phosphorylation was significantly reduced in the experimental groups treated with anti-API5 antibodies No. 1 to 5 compared with the negative control group treated with IgG, resulting in a decrease in ERK phosphorylation as a ratio of total ERK. It was confirmed that this effect occurred in a concentration-dependent manner.

[0116] also, Figure 3 It was shown that in all cancer cell lines, the ERK phosphorylation ratio relative to total ERK in the experimental groups treated with anti-API5 antibodies No. 1 to 5 was reduced to about half compared to the control group not treated with the antibody. These effects were the same in the anti-API5 antibodies No. 1 to 5 of all Examples in a concentration-dependent manner.

[0117] The above results indicate that the anti-API5 antibody having a specific heavy chain CDR sequence of the present invention can reduce ERK activation in cancer cells, thereby exhibiting an excellent anti-cancer effect.

[0118] Example 3-2: Increased apoptosis

[0119] In order to examine the anti-cancer effect of the anti-API5 antibody prepared in Example 1, the effect of the anti-API5 antibody on increasing apoptosis of cancer cells was analyzed.

[0120] TC-1P3 prepared in Example 3-1 PD-1 Non-small cell lung cancer or cervical cancer cell lines and CT26 P3 PD-1 Colorectal cancer cell lines were plated at 3×10 5 Cells were seeded in 12-well plates and RPMI medium containing 5% FBS was used. Two hours later, the medium was replaced with RPMI solvent containing 0.1% FBS, and each anti-API5 antibody was treated at a maximum concentration of 150 ng / mL. After 24 hours, the percentage of apoptotic dead cells was determined using FACS.

[0121] Here, a group not treated with the antibody was set as a control group.

[0122] result, Figure 4 It was shown that in the experimental groups treated with anti-API5 antibodies No. 3 to No. 5 of the present invention, apoptosis of cancer cells increased by about 10% to 20% compared with the control group not treated with the antibody, and these effects were also observed in all cancer cell lines.

[0123] The above results indicate that the anti-API5 antibody having a specific heavy chain CDR sequence of the present invention can increase the sensitivity of cancer cells to apoptosis, thereby exhibiting an excellent anti-cancer effect.

[0124] Example 3-3. Inhibition of tumor growth in vivo

[0125] In order to examine the anti-cancer effect of the anti-API5 antibody prepared in Example 1, the extent of tumor growth was analyzed after the antibody was administered to mice.

[0126] In the experiment, anti-PD-1 antibody was used to treat drug-resistant B16 P3 PD-1 Melanoma cell line, MC-38P0 colorectal cancer cell line, MC-38P3 resistant to anti-PD-1 antibody treatment PD-1 Colorectal cancer cell line MC-38P3 resistant to anti-PD-L1 antibody treatment PD-L1 Colorectal cancer cell line, TC-1P0 non-small cell lung cancer or uterine cancer cell line, CT26 P0 colon cancer cell line, CT26 P3 resistant to anti-PD-1 antibody treatmentPD-1 Colorectal cancer cell lines.

[0127] Specifically, each cell was cultured at 5 × 10 5 The number of cells was transplanted into balb / c mice to form tumors. When the tumor size reached an average of about 60 to 75 mm 3 (MC-38 is 30 to 40 mm 3 ), 8 to 9 mice were assigned to each experimental group so that the tumor size was as evenly distributed as possible in each group, and each antibody was administered. The antibody dose was 200 μg, and it was intraperitoneally injected three times a week from the start day of antibody administration (day 1), for a total of 5 times.

[0128] Thereafter, the length of the tumor was measured with a caliper every 2 or 3 days based on the start date of antibody administration, and the size of the tumor was calculated using the following formula: tumor size = {(long axis length × short axis length) 2} / 2. In addition, the tumor growth inhibition rate (TGI, %) was calculated from the tumor size according to the formula: 100-(100 × experimental group tumor size / IgG antibody-treated control group tumor size).

[0129] The above results were analyzed by assuming that the data were normally distributed and using a parametric multiple comparison procedure. If the results of the parametric two-way ANOVA were significant, a post hoc test was performed using Sidak's multiple comparison test. Statistical analysis was performed using Prism 8.0.1 (GraphPad Software Inc., San Diego, CA, USA), and a P value of less than 0.05 was determined to be statistically significant.

[0130] Here, the group treated with IgG antibody was set as the control group.

[0131] Results, such as Figures 5 to 8 As shown, in the experimental groups treated with anti-API5 antibodies No. 1 to No. 5 of the present invention, tumor growth was significantly inhibited. Compared with the control group treated with IgG antibodies, the tumor growth inhibition effect in the experimental group increased by about 1.5 to 4 times, and this effect was shown not only in cancer cells resistant to existing immune anticancer drugs, but also in various cancers such as melanoma, colorectal cancer, non-small cell lung cancer or cervical cancer.

[0132] Specifically, Fig. 9 It was shown that when the anti-API5 antibody of the present invention is administered in combination with an anti-PD-1 antibody, it also exhibits an excellent growth inhibitory effect on cancer cells that show tolerance, resistance or refractory to anti-PD-1 treatment, and this effect is synergistic.

[0133] In addition, if Fig.10 and 11As shown, in the experimental groups treated with anti-API5 antibodies No. 1 to 4 of the present invention, tumor growth was significantly inhibited. In the experimental groups, the tumor growth inhibition effect increased by about 1.3 to 2 times compared with the control group treated with IgG antibodies, and the tumor growth inhibition rate (TGI) increased by 30.1%, 49.6%, 59.2% and 55.2% respectively compared with the control group.

[0134] The above results show that the anti-API5 antibody having a specific heavy chain CDR sequence of the present invention can exhibit excellent anticancer effects, such as inhibiting the growth of cancer cells in vivo. In particular, this shows that it can exhibit excellent anticancer effects on cancers that are resistant or refractory to anticancer drugs, and also exhibit excellent synergistic effects with drugs that have been used as immunotherapeutic agents.

Claims

1. An antibody or an antigen-binding fragment thereof that specifically binds to apoptosis inhibitor 5 (API5), comprising: A heavy chain CDR1 comprising the amino acid sequence GFTFSTYA set forth in SEQ ID NO: 1; a heavy chain CDR2 comprising the amino acid sequence ISGSGGX1T set forth in SEQ ID NO: 2; and A heavy chain CDR3 comprising the amino acid sequence AKLVLX2WX3YFSMDH shown in SEQ ID NO: 3, wherein X1, X2 and X3 are independently any amino acid.

2. The antibody or antigen-binding fragment thereof according to claim 1, wherein The heavy chain CDR2 comprises the amino acid sequence shown in SEQ ID NO:4 or SEQ ID NO:

5.

3. The antibody or antigen-binding fragment thereof according to claim 1, wherein The heavy chain CDR3 comprises any one amino acid sequence selected from SEQ ID NO: 6 to SEQ ID NO:

10.

4. The antibody or antigen-binding fragment thereof according to claim 1, wherein The antibody comprises a heavy chain variable region, and the heavy chain variable region comprises any one amino acid sequence selected from SEQ ID NOs: 11 to 15.

5. The antibody or antigen-binding fragment thereof according to claim 1, wherein The antibody comprises a light chain CDR1 comprising the amino acid sequence shown in SEQ ID NO: 16; a light chain CDR2 comprising the amino acid sequence shown in SEQ ID NO: 17; and a light chain CDR3 comprising the amino acid sequence shown in SEQ ID NO:

18.

6. The antibody or antigen-binding fragment thereof according to claim 1, wherein The antibody comprises a light chain variable region, and the light chain variable region comprises the amino acid sequence shown in SEQ ID NO:

19.

7. A nucleic acid encoding the antibody or antigen-binding fragment thereof according to claim 1. A vector comprising the nucleic acid according to claim 7.

9. A cell transformed with the vector according to claim 8. 10 . A pharmaceutical composition for preventing or treating cancer, comprising the antibody or antigen-binding fragment thereof according to claim 1 .

11. The pharmaceutical composition according to claim 10, wherein The cancer is resistant or refractory to anticancer drugs.

12. The pharmaceutical composition according to claim 11, wherein The anticancer drug is one or more selected from anticancer chemotherapy drugs, anticancer targeted drugs and anticancer immunotherapy drugs.

13. The pharmaceutical composition according to claim 11, wherein The cancer is selected from the group consisting of lung cancer, non-small cell lung cancer, colorectal cancer, rectal cancer, proximal anal cancer, colon cancer, small intestine cancer, breast cancer, uterine cancer, ovarian cancer, fallopian tube cancer, endometrial cancer, cervical cancer, vaginal cancer, vulvar cancer, head cancer, neck cancer, thyroid cancer, parathyroid cancer, stomach cancer, liver cancer, pancreatic cancer, bone cancer, skin cancer, cutaneous or intraocular melanoma, Hodgkin's disease, esophageal cancer, endocrine cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, penile cancer, prostate cancer, bladder cancer, kidney cancer, ureteral cancer, renal cell carcinoma, renal pelvis cancer, central nervous system tumors, central nervous system lymphomas, spinal cord tumors, glioblastomas, brain stem gliomas, and pituitary tumors.

14. A composition for diagnosing cancer, comprising the antibody or antigen-binding fragment thereof according to claim 1.

15. A kit for diagnosing cancer, comprising the antibody or antigen-binding fragment thereof according to claim 1.

16. A method for providing cancer diagnosis information, comprising: By using the antibody or antigen-binding fragment thereof according to claim 1 to perform an antigen-antibody reaction, the API5 protein in a biological sample isolated from a subject suspected of having cancer is detected or the expression level of the API5 protein is determined.

17. A method for screening anticancer drugs, comprising: (a) treating cancer cells with an anticancer drug candidate; (b) using the antibody or antigen-binding fragment thereof according to claim 1, determining the expression level of API5 protein in cancer cells treated with an anti-cancer drug candidate; and (c) when the API5 protein expression level in step (b) is lower than the API5 protein expression level in cancer cells not treated with the anticancer drug candidate, determining the anticancer drug candidate treated in step (a) as an anticancer drug.